Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.87 HKD | -0.35% | +4.74% | -17.29% |
Apr. 30 | Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets | MT |
Apr. 30 | Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules | CI |
Business Summary
- chemical medicine products and biopharmaceutical drugs (97.6%);
- other (2.4%).
Number of employees: 25,806
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Modernised Chinese Medicines and Chemical Medicines
98.4
%
| 32,830 | 98.1 % | 28,477 | 98.4 % | -13.26% |
Others
1.6
%
| 638 | 1.9 % | 473 | 1.6 % | -25.87% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 33,468 | 100.0 % | 28,950 | 100.0 % | -13.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
S Y Tse
CEO | Chief Executive Officer | 29 | 19-10-22 |
Ping Tse
FOU | Founder | 72 | 00-02-01 |
Chun Ling Li
DFI | Director of Finance/CFO | 53 | - |
Ming Qin Li
BRD | Director/Board Member | 66 | 97-02-28 |
Hsin Tse
BRD | Director/Board Member | 54 | 95-07-31 |
Sean Chen
PRN | Corporate Officer/Principal | 46 | 21-12-31 |
Qian Li
PRN | Corporate Officer/Principal | - | 09-05-31 |
Philip Duong
PRN | Corporate Officer/Principal | 34 | 19-12-31 |
Benjamin Toogood
PRN | Corporate Officer/Principal | 48 | 20-12-31 |
Oi Nin Chan
SEC | Corporate Secretary | 56 | 15-08-24 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ping Tse
FOU | Founder | 72 | 00-02-01 |
Director/Board Member | 60 | 04-12-31 | |
Hsin Tse
BRD | Director/Board Member | 54 | 95-07-31 |
Da Kui Li
BRD | Director/Board Member | 80 | 04-08-31 |
Ming Qin Li
BRD | Director/Board Member | 66 | 97-02-28 |
Zhou Shan Tian
BRD | Director/Board Member | 60 | 97-03-31 |
Hong Lu
BRD | Director/Board Member | 54 | 15-04-19 |
Theresa Tse
CHM | Chairman | 32 | 15-06-29 |
Kwok Tung Li
BRD | Director/Board Member | 69 | 20-12-30 |
S Y Tse
CEO | Chief Executive Officer | 29 | 19-10-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 18,801,217,230 | 9,740,976,595 ( 51.81 %) | 454,093,043 ( 2.415 %) | 51.81 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
1,376,000 | 0.27% | 1,775,728 $ |
Company contact information
Sino Biopharmaceutical Ltd.
Unit 09, 41st Floor, Office Tower Convention Plaza
, Hong Kong
+852 2802 9886
http://www.sinobiopharm.comSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.29% | 6.76B | |
+29.68% | 681B | |
+20.04% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+13.58% | 235B | |
+4.42% | 199B | |
-12.43% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- 1177 Stock
- Company Sino Biopharmaceutical Limited